Myopia control and prevention: From lifestyle to low‐concentration atropine. The 2022 Josh Wallman Memorial Lecture
Authors:
Open Access
- 1 March 2023
- journal article
- research article
- Published by Springer Nature in Ophthalmic and Physiological Optics
- Vol. 43 (3) , 299-310
Abstract
The purpose of this study was to explore the findings from the Hong Kong Children Eye Study and the Low Concentration Atropine for Myopia Progression (LAMP‐1) Study. The incidence of myopia among schoolchildren in Hong Kong more than doubled during the COVID‐19 pandemic, with outdoor time decreased significantly and screen time increased. The change in lifestyle during the COVID‐19 pandemic aggravated myopia development. Low‐concentration atropine (0.05%, 0.025% and 0.01%) is effective in reducing myopia progression with a concentration‐related response. This concentration‐dependent response was maintained throughout a 3‐year follow‐up period, and all low concentrations were well tolerated. An age‐dependent effect was observed in each treatment group with 0.05%, 0.025% and 0.01% atropine. Younger age was associated with a poor treatment response to low‐concentration atropine. Additionally, low‐concentration atropine induced choroidal thickening along a concentration‐dependent response throughout the treatment period. During the third year, continued atropine treatment achieved a better effect across all concentrations compared with the washout regimen. Stopping treatment at an older age and receiving lower concentration were associated with a smaller rebound effect. However, differences in the rebound effect were clinically small across all the three concentrations studied.Keywords
Funding Information
- Health and Medical Research Fund (07180826)
- Health and Medical Research Fund (5160836)
- National Natural Science Foundation of China (82171089)
- Chinese University of Hong Kong (4054634)
- Chinese University of Hong Kong (178662514)
- Chinese University of Hong Kong (4054199)
- Chinese University of Hong Kong (4054121)
- Chinese University of Hong Kong (4054193)
- Innovation and Technology Fund (7010590)
- UBS Optimus Foundation (8984)
This publication has 34 references indexed in Scilit:
- Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2Ophthalmology, 2016
- Analysis of Changes in Refraction and Biometry of Atropine- and Placebo-Treated EyesInvestigative Ophthalmology & Visual Science, 2015
- Risk Factors for Progressive Myopia in the Atropine Therapy for Myopia StudyAmerican Journal of Ophthalmology, 2015
- The myopia boomNature, 2015
- Epidemiology and Disease Burden of Pathologic Myopia and Myopic Choroidal Neovascularization: An Evidence-Based Systematic ReviewAmerican Journal of Ophthalmology, 2014
- Causes of vision loss worldwide, 1990–2010: a systematic analysisThe Lancet Global Health, 2013
- The complex interactions of retinal, optical and environmental factors in myopia aetiologyProgress in Retinal and Eye Research, 2012
- MyopiaThe Lancet, 2012
- Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)Ophthalmology, 2012
- Worldwide prevalence and risk factors for myopiaOphthalmic and Physiological Optics, 2011